Posted by Michael Wonder on 05 Feb 2025
FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness
4 February 2025 - Approval marks the second indication for Susvimo in addition to neovascular or ‘wet’ age-related macular degeneration,
Roche announced today that the US FDA has approved Susvimo (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular oedema, a leading cause of vision loss in adults with diabetes, affecting more than 29 million adults worldwide.
